Tvardi Therapeutics Inc.
TVRD | NASDAQ
$1.68
+$0.07 (+4.35%)
Sep 22, 2026, 1:46 PM ET · Market open
TTM Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q4 2025 Dec 30, 2025 | Q3 2025 Sep 29, 2025 | Q2 2025 Jun 29, 2025 | Q1 2025 Mar 30, 2025 | Q4 2024 Dec 30, 2024 | Q3 2024 Sep 29, 2024 | Q2 2024 Jun 29, 2024 | Q1 2024 Mar 30, 2024 | Q4 2023 Dec 30, 2023 | Q3 2023 Sep 29, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | n/a | n/a | 2.57M | 2.57M | 2.57M | 2.57M | 2.14M | 5.14M | 10.01M | 10.01M | 7.87M | 4.87M |
Cost of Revenue | n/a | 47K | 47K | 47K | 47K | 5K | 625K | 1.32M | 2.93M | 2.93M | 2.31M | 1.62M |
Gross Profit | n/a | -47K | 2.52M | 2.52M | 2.52M | 2.56M | 1.51M | 3.82M | 7.07M | 7.08M | 5.56M | 3.25M |
Operating Income | -27.21M | -29.45M | -24.78M | -28M | -27.73M | -26.05M | -53.33M | -75.13M | -98.35M | -91.17M | -61.51M | -28.9M |
Interest Income | 1.14M | 1.35M | 1.1M | 1.21M | 1.56M | 1.39M | 1.39M | 1.29M | 1.39M | 1.18M | 1.18M | 866K |
Pretax Income | -26.06M | -15.44M | -13.54M | -18.97M | -18.96M | -30.1M | -55.89M | -75.52M | -98.04M | -91.07M | -60.37M | -28.03M |
Net Income | -26.06M | -15.44M | -13.54M | -18.97M | -18.96M | -30.1M | -55.89M | -75.52M | -98.04M | -91.07M | -60.37M | -28.03M |
Selling & General & Admin | 9.2M | 9.63M | 12.13M | 12.23M | 10.78M | 8.36M | 10.51M | 14.86M | 20.7M | 20.06M | 13.27M | 6.72M |
Research & Development | 18.01M | 19.81M | 15.22M | 18.33M | 19.52M | 20.25M | 41.89M | 61.66M | 82.29M | 75.76M | 53.8M | 25.42M |
Other Expenses | n/a | -47K | -47K | -47K | -47K | n/a | 2.43M | 2.43M | 2.43M | 2.43M | n/a | n/a |
Operating Expenses | 27.21M | 29.4M | 27.3M | 30.52M | 30.26M | 28.61M | 54.84M | 78.95M | 105.43M | 98.25M | 67.07M | 32.15M |
Interest Expense | n/a | n/a | 2.87M | 5.49M | 7.45M | 9.36M | 8.47M | 5.85M | 3.89M | 1.98M | n/a | n/a |
Selling & Marketing Expenses | 137K | 137K | 91K | 95K | 93K | 93K | 93K | 43K | n/a | n/a | n/a | n/a |
Cost & Expenses | 27.21M | 29.45M | 27.35M | 30.56M | 30.3M | 28.61M | 55.46M | 80.27M | 108.36M | 101.18M | 69.38M | 33.76M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 9.36M | 9.38M | 9.33M | 9.38M | 8.25M | 9.36M | 1.52M | 1.52M | 1.52M | 9.36M | 9.36M | 1.51M |
Shares Outstanding (Diluted) | 9.38M | 9.38M | 9.38M | 9.38M | 8.46M | 9.36M | 1.52M | 1.52M | 1.52M | 9.36M | 9.36M | 1.51M |
EPS (Basic) | -2.79 | -1.59 | -1.38 | -5.64 | -13.24 | -26.92 | -29.68 | -25.10 | -35.52 | -22.35 | -19.07 | -18.61 |
EPS (Diluted) | -2.79 | -3.10 | -2.89 | -7.15 | -14.75 | -26.92 | -29.68 | -25.10 | -35.52 | -22.35 | -19.07 | -18.61 |
EBITDA | -26.16M | -15.34M | -10.56M | -13.37M | -11.39M | -22.58M | -49.23M | -70.82M | -94.8M | -87.83M | -59.16M | -27.51M |
EBIT | -26.24M | -15.44M | -10.67M | -13.49M | -11.51M | -22.65M | -49.33M | -70.98M | -95.45M | -88.48M | -59.77M | -28.03M |
Depreciation & Amortization | 71K | 95K | 119K | 119K | 119K | 77K | 95K | 153K | 650K | 645K | 603K | 521K |
Add to Watchlist
Select watchlists to add or remove TVRD